When executed with precision and transparency, ECAs can enhance trial efficiency, expand access and support evidence—while ...

Although modern oncology trial design has promoted adaptive designs as a new aspect of clinical trials, we note that adaptive elements have played a long-standing role in oncology clinical trials, ...

LUCIA pivotal Phase 3 trial continues rapid enrollment pace with 60% of patients randomized; enrollment completion expected in 3Q 2025 – – Topline 56-week data for LUGANO expected in mid-2026 with ...

"We view the totality of the data in the NAUTILUS study as a meaningful catalyst that adds to the growing body of evidence and momentum in our business,” said Joel Becker, Chief Executive Officer.

Werner syndrome (WS) is a rare genetic disorder that causes premature aging and serious complications. In the first clinical ...

LEO Pharma A/S, a global leader in medical dermatology, today announced the initiation of the phase 2a proof-of-concept DELTA NEXT trial. The trial aims to evaluate the efficacy and safety of ...

Can the brain recover from addiction? New research shows that mindfulness can restore the addicted brain's ability to savor natural pleasure.

Interim results from the global MATTERHORN study mark the first time an immunotherapy has demonstrated statistically ...

Phase 3-Ready Design Insights: Planning is ongoing for a Phase 3 design similar to the design of ILYX-002-201 de-risking the ...